





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Winicov

Attorney Docket: 5475-US

Serial No:

09/647,841

Group Art Unit: 1638

Filed:

October 5, 2000

Examiner: Baum, S.

For:

Expression Of Alfin 1 And Methods For Producing Transgenic Plants

Having Increased Root Growth And Root Specific Gene Activation

### **AMENDMENT**

To: Assistant Commissioner for Patents Box Non-Fee Amendment Washington, D.C. 20231

Sir:

Responsive to the Official Action dated January 2, 2002, (Paper No. 5), kindly enter the attached sequence listing which is also submitted on a 3.5 diskette.

The content on the paper and the computer readable form is identical to the written paper sequence listing.

A copy of the Notice is also enclosed.

In view of the foregoing, it is respectfully submitted that all of the informalities have been met, and that this application can be passed to examination. If a telephone conference would expedite any proceeding in this application, please contact counsel at the number shown below. Early action to this end is respectfully requested and earnestly urged.

Respectfully submitted,

Richard Myback

Richard R. Mybeck

Reg. No. 17,886



ebruary 4, 2002 Post Office Box 5540 Scottsdale, AZ 85261-5540 480/483-1285 Fax 480/483-7452



RECEIVED

FEB 2 6 2002 TECH CENTER 1600/2900

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box Non-fee Amendment, Washington, D.C. 20231 on the date indicated below.

February 4, 2002



/	OIFE	C
	FEB 19 2010	4
1	TA TRANS	微

# Notice to Comply

Application N . 09/647841	Applicant(s) WINICOV		
Examiner	Art Unit		
Stuart Baum	1638		

# MOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

## Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY